Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015, with the report dated February 2, 2015. The filing serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of January 31, 2015:
- Total Issued Ordinary Shares: 5,355,522,429 (25p each)
- Treasury Shares: 491,515,950
- Total Voting Rights: 4,864,006,479
The document does not explicitly state material changes compared to a prior comparable period, though it provides the definitive denominator for shareholder notification calculations under Financial Conduct Authority rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory capital disclosure.
Investor Verification Checklist
- Verify the total number of voting rights (4,864,006,479) against internal records for compliance with disclosure thresholds.
- Confirm the count of Treasury shares (491,515,950) held as of January 31, 2015.
- Ensure the issued share capital figure (5,355,522,429) aligns with the Company's latest annual report (Form 20-F).